

11 September 2026

## Biologics in Rheumatology

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

| Drug                    | Number of Patients                              |
|-------------------------|-------------------------------------------------|
| Abatacept (Orencia)     | 302 (244 SC + 58 IV)                            |
| Adalimumab (Humira)     | 241                                             |
| Adalimumab Biosimilars  | 1031 (Amgevita 193 + Imraldi 420 + Yuflyma 418) |
| Apremilast (Otezla)     | 0                                               |
| Apremilast (Generic)    | 0                                               |
| Baricitinib (Olumiant)  | 30                                              |
| Bimekizumab (Bimzelx)   | 74                                              |
| Certolizumab (Cimzia)   | 146                                             |
| Etanercept (Enbrel)     | 90                                              |
| Etanercept Biosimilars  | 350 (Benepali)                                  |
| Filgotinib (Jyseleca)   | <5                                              |
| Golimumab (Simponi)     | 87                                              |
| Golimumab Biosimilar    | 8                                               |
| Guselkumab (Tremfya)    | 16                                              |
| Infliximab (Remicade)   | 40                                              |
| Infliximab Biosimilars  | 75 (Remsima IV 70 + Remsima SC 5)               |
| Ixekizumab (Taltz)      | 126                                             |
| Risankizumab (Skyrizi)  | <5                                              |
| Rituximab (MabThera)    | 25                                              |
| Rituximab Biosimilars   | 201 (Truxima)                                   |
| Sarilumab (Kevzara)     | 5                                               |
| Secukinumab (Cosentyx)  | 242                                             |
| Tocilizumab (RoActemra) | 239 (RoActemra 190 + RoActemra IV 49)           |
| Tocilizumab Biosimilars | <5 (Avtozma)                                    |
| Tofacitinib (Xeljanz)   | 26                                              |
| Upadacitinib (Rinvoq)   | 132                                             |
| Ustekinumab (Stelara)   | <5                                              |
| Ustekinumab Biosimilar  | <5 (Uzpruvo)                                    |

**11 September 2026**

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018

.